Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Pieters

Showing results (31-40 of 392) with videos related to

Pageof 40
Sort By:
Therapeutic Drug Monitoring|August 13, 2024
A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic LeukemiaLeiah J Brigitha, Karen Zaky, Rob Pieters, et al.
Personalized Medicine|May 20, 2018
Future perspectives on minimizing bone density reduction in pediatric acute lymphoblastic leukemiaMariël Lizet Te Winkel, Rob Pieters, Marry M van den Heuvel-Eibrink
Haematologica|September 2, 2016
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemiaRui D Mendes, Kirsten Canté-Barrett, Rob Pieters, et al.
Pediatric Blood & Cancer|June 30, 2012
Motor performance and functional exercise capacity in survivors of pediatric acute lymphoblastic leukemiaAnnelies Hartman, Wim Hop, Tim Takken, et al.
Haematologica|June 15, 2023
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic modelRobin Q H Kloos, Ron Mathôt, Rob Pieters, et al.
Pediatric Blood & Cancer|July 5, 2016
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivationRobin Q H Kloos, Rob Pieters, Gabriele Escherich, et al.
Haematologica|April 25, 2020
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic modelRobin Q H Kloos, Ron Mathôt, Rob Pieters, et al.
Haematologica|April 1, 2014
Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginaseWing H Tong, Rob Pieters, Wim J E Tissing, et al.
Gene|March 26, 2013
Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migrationFloor A M Duijkers, Jules P P Meijerink, Rob Pieters, et al.
Leukemia & Lymphoma|August 30, 2024
<i>IKZF1</i> in acute lymphoblastic leukemia: the rise before the fall?Anna Østergaard, Judith M Boer, Frank N van Leeuwen, et al.
Pageof 40

Showing results (31-40 of 392) with videos related to

Sort By:
Pageof 40
Therapeutic Drug Monitoring|August 13, 2024
A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic LeukemiaLeiah J Brigitha, Karen Zaky, Rob Pieters, et al.
Personalized Medicine|May 20, 2018
Future perspectives on minimizing bone density reduction in pediatric acute lymphoblastic leukemiaMariël Lizet Te Winkel, Rob Pieters, Marry M van den Heuvel-Eibrink
Haematologica|September 2, 2016
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemiaRui D Mendes, Kirsten Canté-Barrett, Rob Pieters, et al.
Pediatric Blood & Cancer|June 30, 2012
Motor performance and functional exercise capacity in survivors of pediatric acute lymphoblastic leukemiaAnnelies Hartman, Wim Hop, Tim Takken, et al.
Haematologica|June 15, 2023
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic modelRobin Q H Kloos, Ron Mathôt, Rob Pieters, et al.
Pediatric Blood & Cancer|July 5, 2016
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivationRobin Q H Kloos, Rob Pieters, Gabriele Escherich, et al.
Haematologica|April 25, 2020
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic modelRobin Q H Kloos, Ron Mathôt, Rob Pieters, et al.
Haematologica|April 1, 2014
Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginaseWing H Tong, Rob Pieters, Wim J E Tissing, et al.
Gene|March 26, 2013
Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migrationFloor A M Duijkers, Jules P P Meijerink, Rob Pieters, et al.
Leukemia & Lymphoma|August 30, 2024
<i>IKZF1</i> in acute lymphoblastic leukemia: the rise before the fall?Anna Østergaard, Judith M Boer, Frank N van Leeuwen, et al.
Pageof 40